20/20 Biolabs Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of 20/20 Biolabs Inc (AIDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: 20/20 Biolabs Inc vs Its Competitors
- Peer revenue share: 20/20 Biolabs Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AIDX Sales vs. its Competitors, Q1 2026
20/20 Biolabs Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the IT Infrastructure industry grew revenue 26.5% year over year, combined, vs -36.2% for 20/20 Biolabs Inc. 20/20 Biolabs Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
20/20 Biolabs Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| 20/20 Biolabs, Inc. | - | - | - | - |
| High-Confidence Competitors (1) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AIDX Stock Performance relative to its Competitors
AIDX Stock Performance relative to High-Confidence Competitors
20/20 Biolabs Inc's Competitors Named by the Company
Competitive relationships identified from 20/20 Biolabs Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bioaffinity Technologies Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for 20/20 Biolabs Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from 20/20 Biolabs Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.